These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 23289171)
1. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis]. Széplaki G; Merkely B Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171 [TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. Singer B; Ross AP; Tobias K Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286 [TBL] [Abstract][Full Text] [Related]
3. Fingolimod for the treatment of relapsing multiple sclerosis. Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700 [TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P; N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952 [TBL] [Abstract][Full Text] [Related]
5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L; N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954 [TBL] [Abstract][Full Text] [Related]
6. Fingolimod for relapsing multiple sclerosis: an update. Horga A; Castilló J; Montalban X Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536 [TBL] [Abstract][Full Text] [Related]
7. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Yeh EA; Weinstock-Guttman B Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595 [TBL] [Abstract][Full Text] [Related]
8. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Ward MD; Jones DE; Goldman MD Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Agashivala N; Kim E Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258 [TBL] [Abstract][Full Text] [Related]
10. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Camm J; Hla T; Bakshi R; Brinkmann V Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790 [TBL] [Abstract][Full Text] [Related]
11. Delayed fingolimod-associated asystole. Espinosa PS; Berger JR Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609 [TBL] [Abstract][Full Text] [Related]
12. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod]. Komoly S Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178 [No Abstract] [Full Text] [Related]
13. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism]. Tar L; Vécsei L Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Tanasescu R; Constantinescu CS Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791 [TBL] [Abstract][Full Text] [Related]
15. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L; Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956 [TBL] [Abstract][Full Text] [Related]